Actimab-A: Interim Phase I/II data

Interim data from 9 evaluable AML patients ages =60 in an open-label, U.S. Phase I/II trial showed that Actimab-A plus low-dose cytarabine led to a median overall survival (OS) of 5.4 months. In 7 of ...